TICE | Startup India’s Post

Imagine an AI platform that could guide cancer patients through the most critical stages of their journey—taking the guesswork out of treatment, reducing delays, and providing precision care… That’s exactly what Shemha Health Ltd. is doing with PrOPA™️. 🚀 PrOPA by Shemha Health. In our latest blog, we explore how Shemha’s founders turned their personal experiences into a mission to change cancer care forever. 🏥 Their AI-powered platform combines real-world data with clinical guidelines, making personalised cancer treatment faster and more efficient than ever before. From partnerships with top cancer centers to real success stories like a lung cancer 🩻diagnosis with 95% accuracy, Shemha Health is proving that AI and human empathy can revolutionize oncology. And they’re not stopping there—with plans to expand globally, including emerging markets, they’re just getting started.👏 📖 Dive deeper into Shemha’s inspiring journey on this blog post https://lnkd.in/dCwFvHTu Let us know in the comments how you think AI will shape the future of healthcare. 👇 . #startups #labenaventures #labena #accelerator #acceleratorprogramme #akcelerator #healthtech #founders #investing #entrepreneurship #preseed #incubator #cee #centralandeasterneurope #ai #aicancer #cancertreatment #shemhahealth

#DOP Approves Six Startups Under #PRIP Scheme, assures support for further clinical studies (#clinicaltrials) Appreciating the efforts of #NIPER Ahmedabad, Pfizer, and Social Alpha in empowering innovative startups focused on critical health issues like breast cancer, cervical cancer, gastrointestinal cancer, and kidney disease, Dr Arunish Chawla announced that six startup which had secured additional funding under the Promotion of Research and Innovation in #PharmaMedTech (#PRIP) scheme, with DOP approval, and expressed confidence that these Research-Linked Incentive (#RLI) recipients would receive vital support to transition from innovative ideas to real-world solutions. #departmentofpharmaceuticals #dop #RLI #medTech #pharma #prip #indianpharma #research #clinicaltrial

Our portfolio company 52North - creators of Neutrocheck® has raised $6m to bring better healthcare to people living with cancer! This is the first investment round co-led in its majority by leading hospitals from both the UK and the US—UK-based @KHP Ventures and US-based Cedars-Sinai Intellectual Property Co.—positioning 52North to advance its products towards the market on a global scale and help patients of all backgrounds manage severe chemotherapy side-effects more safely. 52North is improving urgent pathways in oncology care with innovative, cost-effective medical devices like Neutrocheck. Neutrocheck provides a rapid and reliable result at-home to help doctors more effectively identify patients at risk of neutropenic sepsis (NS) – a serious side-effect of chemotherapy. This pathway reduces unnecessary visits to A&E and unnecessary antibiotic treatment for patients not at-risk, whilst also identifying at-risk patients earlier on, enabling them to be treated more quickly. A huge congratulations to the 52North team. This was an exciting opportunity for us to invest in impact, and we look forward to supporting you on your journey! Read the full press release here: https://shorturl.at/65hGA Cancer Research Horizons, Cambridge Enterprise Ventures, Macmillan Cancer Support, OKG Capital #OnMyHorizon #Oncology #SeedFunding #MedTech #Healthcare

Healthtech Startup 4baseCare Secures $6M to Enhance Cancer Care Solutions Healthtech startup 4baseCare has successfully secured $6 million in its latest funding round, spearheaded by Yali Capital, with participation from a group of undisclosed investors. This fresh injection of capital will be strategically utilized to enhance and expand 4baseCare’s product offerings, with a strong focus on advancing genomics and digital health solutions tailored for cancer care. The company has been at the forefront of developing personalized oncology solutions, aiming to bridge the gap in cancer care through innovative technology and research. This new funding will empower 4baseCare to accelerate its mission of providing cutting-edge cancer care solutions that are accessible and affordable. This milestone follows a $2 million Pre-Series A funding round in 2021, demonstrating the continued confidence and support from investors in the company’s vision and growth trajectory. #Healthtech #CancerCare #4baseCare #Genomics #DigitalHealth #StartupFunding #YaliCapital #Innovation #Healthcare #BPlanadvisors #Buildingbusinesses

Reliance Industries Limited entered Healthcare by acquiring Karkinos Healthcare Mukesh Ambani has made a significant move into the healthcare sector by acquiring Karkinos Healthcare for ₹375 crore Reliance has always had an interest in the oncology sector. Before the acquisition, they had already invested in them RIL aims to integrate cutting-edge technology into healthcare delivery, by acquiring Karkinos, Reliance aims to enhance its portfolio and contribute to cancer care in India 🇮🇳 Reliance Strategic Business Ventures Ltd acquired Karkinos through an allotment of 1 crore equity shares and 36.5 crore optionally fully convertible debentures But why Karkinos? ✅ The company had a turnover of ₹22 crore in the fiscal year 2022-23 ✅ It has innovative cancer solutions like Advanced Cancer Care Diagnostics and Research (ACCDR) and Distributed Cancer Care Network (DCCN) ✅ Tie up with 60 hospitals and collaborations with corporates for early cancer diagnosis TATA SONS LIMITED and Mayo Clinic have also invested in this healthcare startup which underscores the startup's potential What's your view on this which Reliance Industries Limited took now, we have seen what happened in Dunzo 🤔

🚀 BillionToOne Secures $130M to Expand Screening and Oncology Businesses! 🧬 We are thrilled to announce that BillionToOne, a molecular diagnostics pioneer, has raised $130M in an oversubscribed Series D funding round! This funding will drive the expansion of their groundbreaking prenatal screening and oncology diagnostics businesses. 📈 Key Highlights: -Funding Round Led by: Premji Invest, with substantial contributions from Neuberger Berman and existing investors including Baillie Gifford, Adam Street Partners, Hummingbird Ventures, Libertus Capital, Civilization Ventures, and Fifty Years. -Innovative Technology: BillionToOne’s Quantitative Counting Templates (QCTs) technology has been instrumental in developing their diagnostic tests. -Impressive Reach: Over 500,000 patients have benefitted from their diagnostics, generating $125M in annual recurring revenue in just four years. -UNITY Fetal Risk Screen: The first prenatal test capable of assessing fetal risk for genetic conditions without partner samples. -Oncology Liquid Biopsy Products: Northstar Select and Northstar Response offer superior detection and monitoring for late-stage cancer patients. 🔬 Advanced Capabilities: -Northstar Select: Detection limit up to 5x lower than competing assays. -Northstar Response: Offers 10x the precision of single nucleotide variant-based assays. 🎯 Looking Ahead: With this latest funding, BillionToOne’s total capital raised approaches $400M. The company is poised to further revolutionize the diagnostics landscape, enhancing options for clinicians across various specialties. 💬 Quote from Akshay Rai: “BillionToOne has made great progress in transforming the prenatal segment and we are excited by the platform’s potential in expanding diagnostics options available to clinicians in other specialties.” Congratulations to the BillionToOne team for this incredible milestone! #Biotech #Diagnostics #FundingNews #Innovation #PrenatalScreening #Oncology #LiquidBiopsy #Healthcare #MedicalResearch #StartupSuccess #InvestInHealth 💡💉📈

"Over the past five years, oncology health tech companies have raised over $16 billion of venture capital, reaching a peak of $5 billion in 2021. While mortality rates from cancer have declined due to advances in screening and treatment and lower rates of smoking, the number of new cancer cases has remained steady; there has also been a recent, puzzling rise in cancer rates among younger populations. While technological innovations have lowered mortality rates, it is becoming increasingly difficult to reduce death rates further, as much of the low-hanging fruit in cancer care innovation has already been accomplished. Demand for the latest innovations in cancer care technologies should remain strong, and cancer is expected to contribute to overall healthcare costs significantly. Assuming a conservative compound annual growth rate of 4% and a current market size of $250 billion, we expect the oncology health tech market to expand to over $400 billion within the next decade, providing ample opportunity for startups to take share—or find successful exit outcomes—even in a market largely dominated by incumbents." Taken from the recently published Oncology Healthtech VC Market Snapshot by PitchBook. Source: https://lnkd.in/eFsidxBP

UK medtech startup 52North bags €5.7M to accelerate oncology-focused innovations: On Wednesday, Cambridge, UK-based 52North, the medtech company focused on transforming urgent care pathways in oncology, announced that it has secured $6M (approximately €5.7M) in a funding round. The funding round was co-led by KHP Ventures, affiliated with King’s Health Partners in London, and Cedars-Sinai Intellectual Property Co. in California, affiliated with Cedars-Sinai Medical Center. ... Read more #UKMedtech #52North #Oncology

ErlySign raises $1.8 Mn in pre-Series A round from Ashish Kacholia: Healthtech startup ErlySign has raised Rs 16 crore ($1.8 million) in its pre-Series A round from Ashish Kacholia.  The proceeds will be used in clinical trials, securing CDSCO (Central Drugs Standard Control Organisation) approvals, and bringing ErlySign’s oral cancer detection kit to market.  Founded in 2019 by Shubhendra Singh Thakur and Deovrat Begde, ErlySign develops solutions for early detection of oral cancer.  The startup also claims to offer India’s first salivary biomarker-based test which can identify pre-cancerous conditions much before visible symptoms emerge.  Looking ahead, ErlySign plans to use CRISPR miRNA-based testing technology to detect multiple types of cancer using the same saliva sample within 15–20 minutes.  #Healthtech #Startup #Investment

Cancer focused biotech startup Immuneel Therapeutics Pvt. Ltd. has raised Rs 100 crore from TAIBA Middle East FZ LLC. 💰 This marks the company’s fourth Series A round after raising $11 million in 2019, $1.4 million in 2020, and $15 million in 2022 from investors including F-Prime Capital, Khosla Ventures, and Eight Roads Ventures. The round appears to be ongoing. Immuneel Therapeutics was founded in 2018 by Biocon founder Kiran Mazumdar Shaw, Pulitzer Prize winner Siddhartha Mukherjee, and Kush Parker.  The Bengaluru-based startup aims to make CAR-T cell therapy commercially available to patients in India at affordable prices and is developing the country’s first Phase 2 trial for CD19 CAR-T(IMN-003A) for B cell malignancies (Leukemia & Lymphoma). Read more at the link in our comments section below 👇 #FundingWithYS #Funding #Startups